CDw52-specific antibody for treatment of multiple sclerosis

Abstract

The invention relates to the use of an antibody recognising the CDw52 antigen in the treatment of multiple sclerosis. Preferably the antibody is the humanised antibody in the humanised antibody CAMPATH-1H.

1 . A method for the treatment of a human subject suffering from multiple sclerosis which comprises administering to the said subject an effective amount of an antibody recognising the CDw52 antigen.  
     
     
         2 . A method according to  claim 1  wherein the antibody is a humanised antibody including CDRs from mouse or rat antibody combined with framework regions and constant domains from one or more human antibodies.  
     
     
         3 . A method according to  claim 2  wherein the antibody is CAMPATH-1H.  
     
     
         4 . A method in accordance with  claim 1 ,  2  or  3 , wherein the antibody is administered daily at a dose ranging from 1 to 100 mg per day for a period of 1 to 30 days.  
     
     
         5 . A method in accordance with  claim 4 , wherein the antibody is administered daily at a dose ranging from 1 to 10 mg per day.  
     
     
         6 . A method in accordance with  claim 1 ,  2  or  3 , which further comprises the administration of a steroid.  
     
     
         7 . A method in accordance with  claim 6 , wherein the steroid is a hydrocortisone.  
     
     
         8 . A method in accordance with  claim 3 , wherein the antibody was produced in CHO cells.